choriogonadotropin alfa

This medicine is authorised for use in the European Union.


Ovitrelle is a medicine used in women who have received treatment to stimulate their ovaries, to trigger ovulation (the release of an egg from the ovaries) and the development of a special structure on the ovary (the corpus luteum) that helps pregnancy.

It can be used in women who are undergoing fertility treatment (such as in vitro fertilisation), and in women who are anovulatory (do not produce eggs) or oligo-ovulatory (rarely produce eggs).

Ovitrelle contains the active substance choriogonadotropin alfa.

This EPAR was last updated on 17/11/2022

Authorisation details

Product details
Agency product number
Active substance
choriogonadotropin alfa
International non-proprietary name (INN) or common name
choriogonadotropin alfa
Therapeutic area (MeSH)
  • Anovulation
  • Reproductive Techniques, Assisted
  • Infertility, Female
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Merck Europe B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Gustav Mahlerplein 102
1082 MA Amsterdam
The Netherlands

Product information

16/11/2022 Ovitrelle - EMEA/H/C/000320 - N/0087

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Sex hormones and modulators of the genital system

Therapeutic indication

Ovitrelle is indicated in the treatment of:

  • women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (IVF): Ovitrelle is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth;
  • anovulatory or oligo-ovulatory women: Ovitrelle is administered to trigger ovulation and luteinisation in anovulatory or oligo-ovulatory patients after stimulation of follicular growth.

Assessment history

How useful was this page?

Add your rating
3 ratings